SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):320P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Versari, A.
Right arrow Articles by Salvo, D.
PubMed
Right arrow Articles by Versari, A.
Right arrow Articles by Salvo, D.

Oncology-Basic Science: Therapy, Metrics & Intervention

Therapy, Metrics & Intervention Posters

90Y-DOTATOC in the treatment of metastatic neuroendocrine tumors: Preliminary results

Annibale Versari1, Alessandro Fraternali1, Andrea Frasoldati2, Amalia Carpi3, Mattia Asti1, Angelina Filice1, Maria Di Paolo1, Federica Fioroni4 and Diana Salvo1

1 Nuclear Medicine; 2 Endocrinology; 3 Oncology; 4 Medical Physics, S. Maria Nuova Hospital, Reggio Emilia, Italy

1359

Objectives: Somatostatin receptors are over-expressed in most neuroendocrine tumors (NETs): radiolabelled somatostatin analogs can be used for imaging and therapy of these neoplasms. Aim of this study is to evaluate the utility of the radiolabelled somatostatin analog 90Y-DOTA-D-Phe1 -Tyr3-octreotide (90Y-DOTATOC) in the palliative treatment of NETs.

Methods: Twenty patients (pts), m/f 10/10, age 40-83 yrs (mean 68), with metastatic unresectable somatostatin-receptor-positive NETs, were treated with 90Y-DOTATOC. The suitability for treatment was evaluated with 68Ga-DOTATOC PET/CT and the dose calculated by means of 111In-DOTATOC scintigraphy. The primary sites were pancreas (5), ileum (4), lung (2); nine were unknown. Response was documented by clinical, biochemical and PET/CT findings.

Results: Ten GBq to be divided in 4-5 administrations (once every 3 months) was the decided maximum cumulative dose. Two pts had 4 administrations, five pts 3, nine pts 2 and four pts 1. The responses were as follows: progression in 3 pts (1 death), stable disease in 14 and partial remission in 3. The clinical response resulted higher than biochemical and PET/CT findings. The PET/CT improvement was superior in liver metastases than in other tissues. As parameter for response evaluation, SUV tumor/non-tumor ratio performed better than SUV alone. No serious side effects arised.

Conclusions: Palliative therapy of NETs with radiolabelled somatostatin analogs is very promising and safe. The use of the same peptide (DOTATOC) for diagnosis, dose calculation and treatment makes the procedure more reliable.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Versari, A.
Right arrow Articles by Salvo, D.
PubMed
Right arrow Articles by Versari, A.
Right arrow Articles by Salvo, D.